Compare BlackRock TCP Capital Corp (TCPC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackRock TCP Capital Corp vs TG Therapeutics Inc — how do they compare? BlackRock TCP Capital Corp trades at $4.01 (market cap $337.71M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 24.2× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold BlackRock TCP Capital Corp for 88 Days and TG Therapeutics Inc for 16 Days on average.
| TCPC | TGTX | |
|---|---|---|
Market Cap | $337.71M | $8.16B |
Volume | 436,109 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $6.20 | $59.06 |
52-Week Low | $3.13 | $26.94 |
Typical Hold Time | 88 Days | 16 Days |
Enterprise Value | $1.09B | $8.37B |
Dividend Yield | 18.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TCPC trades at $4.03, up 2.28% today, with a bullish technical signal from moving averages. The company reported negative revenue and net income for 2025 but beat Q2 2026 earnings expectations. Recent portfolio sales have reduced leverage and prompted a strategic review. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
The outlook remains cautious due to negative profitability metrics and declining revenue trends, though recent strategic moves and technical strength offer potential upside. Key risks include ongoing negative cash flow, class action lawsuits, and execution challenges in the private credit market.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
